The predictive performance of the three hormone receptor measuring methods was equal also with regards to OS, with HRs for tamoxifen treatment at 10 years follow-up around 0.80 for patients with tumours ER+ or PR+ by any method, and around 0.65 at full follow-up (Supplementary Figure S2–S3 and Table 2). This evidence concerns the gene NR4A1 and neoplasm.